U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C8H15N7O2S3
Molecular Weight 337.445
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FAMOTIDINE

SMILES

NC(=N)NC1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1

InChI

InChIKey=XUFQPHANEAPEMJ-UHFFFAOYSA-N
InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

HIDE SMILES / InChI
Molecular Formula C8H15N7O2S3
Molecular Weight 337.445
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/famotidine.html

Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. Famotidine binds competitively to H2-receptors located on the basolateral membrane of the parietal cell, blocking histamine affects. This competitive inhibition results in reduced basal and nocturnal gastric acid secretion and a reduction in gastric volume, acidity, and amount of gastric acid released in response to stimuli including food, caffeine, insulin, betazole, or pentagastrin.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier.

Originator

Approval Year

1986
107
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
 0.3 µM [IC50]
Inhibitor
8504
 6.7 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

1986
Curative
Approved
8583
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

1986
Primary
Approved
8583
PEPCID

Approved Use

PEPCID is indicated in: 1. Short-term treatment of active duodenal ulcer. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Short-term treatment of active benign gastric ulcer. 4. Short-term treatment of gastroesophageal reflux disease (GERD). PEPCID is indicated for shortterm treatment of patients with symptoms of GERD PEPCID is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas)

Launch Date

1986
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
73 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
424 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
82.5%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019462s039lbl.pdf
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
FAMOTIDINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.5 mg/kg 2 times / day steady, oral
Recommended
Dose: 0.5 mg/kg, 2 times / day
Route: oral
Route: steady
Dose: 0.5 mg/kg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
unhealthy, 11 - 15 years
Health Status: unhealthy
Age Group: 11 - 15 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Other AEs: Dizziness, Dry skin...
Other AEs:
Dizziness (grade 1, 2 patients)
Dry skin (grade 1, 1 patient)
Insomnia (grade 1, 1 patient)
Gastrointestinal disorder (NOS) (grade 1, 1 patient)
Forgetfulness (grade 1, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
1 mg/kg 1 times / day steady, intravenous
Recommended
Dose: 1 mg/kg, 1 times / day
Route: intravenous
Route: steady
Dose: 1 mg/kg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
unhealthy, 6 - 15 years
Health Status: unhealthy
Age Group: 6 - 15 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
Sources:
https://pubmed.ncbi.nlm.nih.gov/7846741/
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Other AEs: Anemia, Nausea...
Other AEs:
Anemia (2 patients)
Nausea (6 patients)
Dyspepsia (5 patients)
Diarrhea (5 patients)
Constipation (4 patients)
Abdominal pain upper (3 patients)
Gastroesophageal reflux disease (2 patients)
Vomiting (2 patients)
Stomach discomfort (2 patients)
Abdominal pain (2 patients)
Edema peripheral (2 patients)
Arthralgia (1 patient)
Back pain (2 patients)
Headache (3 patients)
Hypertension (3 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
AEs

AEs

AESignificanceDosePopulation
Dry skin grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Forgetfulness grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Gastrointestinal disorder (NOS) grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Insomnia grade 1, 1 patient
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Dizziness grade 1, 2 patients
80 mg 3 times / day steady, oral
Highest studied dose
Dose: 80 mg, 3 times / day
Route: oral
Route: steady
Dose: 80 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
unhealthy, 20 - 70 years
Health Status: unhealthy
Age Group: 20 - 70 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/32499303/
Arthralgia 1 patient
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Abdominal pain 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Anemia 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Back pain 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Edema peripheral 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Gastroesophageal reflux disease 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Stomach discomfort 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Vomiting 2 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Abdominal pain upper 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Headache 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Hypertension 3 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Constipation 4 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Diarrhea 5 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Dyspepsia 5 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Nausea 6 patients
26.6 mg 3 times / day steady, oral
Highest studied dose
Dose: 26.6 mg, 3 times / day
Route: oral
Route: steady
Dose: 26.6 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/23024710/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2252
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2B6
926

CYP2C19
2057

OCT1
620

OCT2
779

OCT3
159

MATE1
415

MATE2
267
OCT2
434
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 weak
likely (co-administration study)
Comment: may lead to substantial increases in blood concentrations of tizanidine, a CYP1A2 substrate; can't find inhibition value
Page: 6.0
OCT2
782
 yes [IC50 114 uM]
OCT1
656
 yes [IC50 28 uM]
OCT3
161
 yes [IC50 6.7 uM]
CYP2B6
1160
 yes [Inhibition 100 uM]
CYP2C19
2141
 yes [Inhibition 100 uM]
CYP3A4
2633
 yes [Inhibition 100 uM]
MATE1
416
 yes [Ki 0.6 uM]
MATE2
267
 yes [Ki 9.7 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
OCT2
434
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:4975
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4975
ChemicalBook
CB5706585
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5706585
eMolecules
538460
https://www.emolecules.com/cgi-bin/more?vid=538460
eMolecules
6842898
https://www.emolecules.com/cgi-bin/more?vid=6842898
eMolecules
901873
https://www.emolecules.com/cgi-bin/more?vid=901873
MolPort
MolPort-002-557-620
https://www.molport.com/shop/molecule-link/MolPort-002-557-620
MolPort
MolPort-003-666-342
https://www.molport.com/shop/molecule-link/MolPort-003-666-342
MolPort
MolPort-003-941-395
https://www.molport.com/shop/molecule-link/MolPort-003-941-395
MolPort
MolPort-006-069-255
https://www.molport.com/shop/molecule-link/MolPort-006-069-255
Selleck Chemicals
famotidine-pepcid
http://www.selleckchem.com/products/famotidine-pepcid.html
ZINC
ZINC000001530636
http://zinc15.docking.org/substances/ZINC000001530636
PubMed

PubMed

TitleDatePubMed
Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
1991 Apr
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure.
1992 Mar
[Tolerance of famotidine. Study of network of sentinel physicians in pharmaco-vigilance].
1992 May-Jun
[A case of rheumatoid arthritis associated with autoimmune hemolytic anemia due to weekly low-dose methotrexate therapy].
2000 Aug
Acute cholestatic hepatitis in a child treated with famotidine.
2000 Dec
Amantadine-induced cortical myoclonus.
2001 Jan 23
Double-blind, placebo-controlled trial of famotidine in children with abdominal pain and dyspepsia: global and quantitative assessment.
2001 May
Control of intragastric acidity with over-the-counter doses of ranitidine or famotidine.
2001 Oct
Delirium following a switch from cimetidine to famotidine.
2001 Sep
Effects of H(2)-receptor antagonists on dapsone-induced methaemoglobinaemia in rats.
2002 Apr
Effects of omeprazole and famotidine on fibroblast growth factor-2 during artificial gastric ulcer healing in humans.
2002 Apr
Histamine regulation of interleukin-18-initiating cytokine cascade is associated with down-regulation of intercellular adhesion molecule-1 expression in human peripheral blood mononuclear cells.
2002 Jan
[Use of H2-receptor blocker famotidine (quamatel) in anesthesiology for cardiopulmonary bypass surgery].
2002 Jan-Feb
H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures.
2002 Jul
Ranitidine reduces ischemia/reperfusion-induced liver injury in rats by inhibiting neutrophil activation.
2002 Jun
Randomized comparative study of omeprazole and famotidine in reflux esophagitis.
2002 Sep
Histamine inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production in an intercellular adhesion molecule-1- and B7.1-dependent manner.
2003 Feb
Omeprazole-induced acute interstitial nephritis.
2003 Feb 21
[A successfully treated case of intraoperative latex anaphylaxis during abdominal aorta aneurysm resection].
2003 Jan
Radioprotective properties of histamine H2 receptor antagonists: present and future prospects.
2003 Jun
Effect of exogenous administration of transforming growth factor-beta and famotidine on the healing of duodenal ulcer under the impact of indomethacin.
2003 Jun
On the mechanisms underlying histamine induction of gastric mucosal lesions in rats with partial gastric vascular occlusion.
2003 Jun
Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial.
2003 May 1
The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
2004 Dec
Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.
2004 May
Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A).
2004 Oct 25
Effects of cimetidine-like drugs on recombinant GABAA receptors.
2004 Oct 8
Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3.
2004 Sep
Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis.
2005 Feb
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection and the healing of endoscopic mucosal resection-induced ulceration.
2005 Jun
New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline.
2005 Jun
Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies.
2005 Jun
Effect of preoperative short course famotidine on TILs and survival in breast cancer.
2005 Oct-Dec
Assessing the efficacy of famotidine and rebamipide in the treatment of gastric mucosal lesions in patients receiving long-term NSAID therapy (FORCE--famotidine or rebamipide in comparison by endoscopy).
2006 Dec
Is the monkey an appropriate animal model to examine drug-drug interactions involving renal clearance? Effect of probenecid on the renal elimination of H2 receptor antagonists.
2006 Mar
Coagulation-dependent gene expression and liver injury in rats given lipopolysaccharide with ranitidine but not with famotidine.
2006 May
Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
2006 Oct
Impact of blockade of histamine H2 receptors on chronic heart failure revealed by retrospective and prospective randomized studies.
2006 Oct 3
The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial.
2007 Jan
Gastric antisecretory drugs induce leukocyte-endothelial cell interactions through gastrin release and activation of CCK-2 receptors.
2007 Oct
A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.
2008
Can negative cardiac effect of proton pump inhibitor and high-dose H2-blocker have clinical influence on patients with stable angina?
2008 Aug
Gastroprotective and anti-oxidative properties of ascorbic acid on indomethacin-induced gastric injuries in rats.
2008 Winter
Comparison of the effects of omeprazole and famotidine in treatment of upper abdominal symptoms in patients with reflux esophagitis.
2009
Cytokine responses of intraepithelial lymphocytes are regulated by histamine H(2) receptor.
2009
Phosphodiesterase isozymes involved in regulating acid secretion in the isolated mouse stomach.
2009 Dec
Hepatitis following famotidine: a case report.
2009 Jan 27
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
2009 Jun
Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study.
2010 Apr
Patents

Patents

05021582
2
JP2000197427A
2
JP2000219625A
2
JP2000302679A
2
JP2001302510A
2
JP2002017866A
2
JP2002087958A
2
JP2002145776A
2
JP2002291901A
2
JP2002322057A
2
JP2002511777A
420
JP2002537317A
97
JP2002538104A
9
JP2003088495A
2
JP2003095946A
2
JP2003206229A
2
JP2003212772A
2
JP2003261449A
2
JP2003275318A
2
JP2003275324A
2
JP2003275325A
2
JP2003284722A
2
JP2003305122A
2
JP2003515553A
3
JP2004223027A
2
JP2004261566A
2
JP2005168980A
2
JP2006089393A
2
JP2006273819A
2
JP2007008845A
5
JP2007055905A
2
JP2007284453A
2
JP2007507425A
18
JP2007518689A
11
JP2007525670A
150
JP2008504040A
2
JP2009526755A
475
JP2010088502A
2
JP2011079841A
5
JP2011223965A
2
JP2011229496A
2
JP2011525178A
25
JP2011528275A
456
JP4664289B2
2
JP4722295B2
105
JP4732696B2
68
JP4739217B2
51
JP4756823B2
22
JP4763957B2
87
JP4787165B2
104
JPH01100162A
2
JPH01197439A
2

Sample Use Guides

In Vivo Use Guide
The recommended adult oral dosage for active duodenal ulcer is 40 mg once a day at bedtime. Most patients heal within 4 weeks.
Route of Administration: Oral
In Vitro Use Guide
Famotidine (10-1,000 µM) inhibited methadone and oxycodone cytochrome P450-dependent metabolism >50%.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:11:48 GMT 2025
Edited
by admin
on Mon Mar 31 18:11:48 GMT 2025
Record UNII
5QZO15J2Z8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FAMOTIDINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
PEPCID COMPLETE COMPONENT FAMOTIDINE
Preferred Name English
FLUXID
Brand Name English
GASTER
Brand Name English
MUCLOX
Brand Name English
AMFAMOX
Brand Name English
FAMOXAL
Brand Name English
PEPDUL
Brand Name English
Famotidine [WHO-DD]
Common Name English
[1-Amino-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propylidene]sulfamide
Systematic Name English
FAMOTIDINE [MART.]
Common Name English
PEPCIDINE
Brand Name English
FAMOTIDINE [JAN]
Common Name English
LECEDIL
Brand Name English
MOTIAX
Brand Name English
L 643341
Code English
GANOR
Brand Name English
FAMOTIDINE [MI]
Common Name English
famotidine [INN]
Common Name English
GASTRIDIN
Brand Name English
FAMODIL
Brand Name English
FAMOTIDINE [VANDF]
Common Name English
FAMOTIDINE [USP MONOGRAPH]
Common Name English
YM-11170
Code English
GASTROPEN
Brand Name English
PROPANIMIDAMIDE, N'-(AMINOSULFONYL)-3-(((2-((DIAMINOMETHYLENE)AMINO)-4-THIAZOLYL)METHYL)THIO)-
Systematic Name English
FAMOTIDINE [USP IMPURITY]
Common Name English
FAMOTIDINE [HSDB]
Common Name English
PEPCIDAC
Brand Name English
PEPDINE
Brand Name English
FADUL
Brand Name English
FAMOTIDINE [USP-RS]
Common Name English
FAMOTIDINE [USAN]
Common Name English
FAMOTIDINE [ORANGE BOOK]
Common Name English
FAMOSAN
Brand Name English
PEPCID
Brand Name English
FAMOTIDINE [EP MONOGRAPH]
Common Name English
NSC-757810
Code English
MK-208
Code English
3-((((2-(DIAMINOMETHYLENE)AMINO)-4-THIAZOLYL)METHYL)THIO)-N-SULFAMOYLPROPIONAMIDINE
Common Name English
Classification Tree Code System Code
WHO-ATC A02BA03
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
NDF-RT N0000175784
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
WHO-VATC QA02BA03
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
NCI_THESAURUS C29702
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
WHO-ATC A02BA53
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
LIVERTOX NBK548228
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
WHO-VATC QA02BA53
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
NDF-RT N0000000151
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
Code System Code Type Description
LACTMED
Famotidine
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
EPA CompTox
DTXSID5023039
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
DRUG BANK
DB00927
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
NSC
757810
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
MESH
D015738
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
EVMPD
SUB07503MIG
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
DAILYMED
5QZO15J2Z8
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
INN
5217
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
SMS_ID
100000092363
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
IUPHAR
7074
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
PUBCHEM
3325
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
MERCK INDEX
m5241
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY Merck Index
ChEMBL
CHEMBL902
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
RXCUI
4278
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
FAMOTIDINE
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
RS_ITEM_NUM
1269200
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
CHEBI
4975
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
DRUG CENTRAL
1129
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
USAN
W-33
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
HSDB
3572
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
NCI_THESAURUS
C29045
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
FDA UNII
5QZO15J2Z8
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
CAS
76824-35-6
Created by admin on Mon Mar 31 18:11:48 GMT 2025 , Edited by admin on Mon Mar 31 18:11:48 GMT 2025
PRIMARY
Related Record Type Details
OCT-1
TRANSPORTER -> INHIBITOR
Structure of FAMOTIDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
MATE-2
TRANSPORTER -> INHIBITOR
OAT-1
TRANSPORTER -> INHIBITOR
IC50
Structure of FAMOTIDINE
EXCRETED UNCHANGED
Following IV administration
URINE
HISTAMINE H2 RECEPTOR
TARGET->INVERSE AGONIST
The mean minimum daily requirement of famotidine to control gastric acid hypersecretion was 0.24 g (range 0.08–0.48 g) compared with 2.1 g (range 0.6–3.6 g) for ranitidine and 7.8 g (range 1.2–13.2 g) for cimetidine. is nine times more potent than ranitidine and 32 times more potent than cimetidine, has a longer duration of action than ranitidine or cimetidine,
OCT-2
TRANSPORTER -> INHIBITOR
IC50
OCT-1
TRANSPORTER -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
HISTAMINE H2 RECEPTOR
TARGET->INVERSE AGONIST
MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1
TRANSPORTER -> INHIBITOR
OCT-3
TRANSPORTER -> INHIBITOR
OAT-3
TRANSPORTER -> NON-INHIBITOR
IC50
Structure of FAMOTIDINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Related Record Type Details
Structure of FAMOTIDINE SULFOXIDE
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of FAMOTIDINE CYANOAMIDINE
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-((2-(DIAMINOMETHYLENEAMINO)THIAZOL-4-YL)METHYLTHIO)PROPANIMIDAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE PROPANAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE PROPIONIC ACID
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE PROPANAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of FAMOTIDINE DIMER
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 2.5
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of FAMOTIDINE SULFAMOYL PROPANAMIDE
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.9
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of FAMOTIDINE DIMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE DISULFIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE SULFAMOYL PROPANAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE CYANOAMIDINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of FAMOTIDINE PROPIONIC ACID
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 1.7
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 3-((2-(DIAMINOMETHYLENEAMINO)THIAZOL-4-YL)METHYLTHIO)PROPANIMIDAMIDE
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.19
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of FAMOTIDINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966